Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

SCORE STUDY REPORT 12: Development of Venous Collaterals in the Score Study

Weinberg, David V. MD*; Wahle, Aimee E. MS; Ip, Michael S. MD; Scott, Ingrid U. MD, MPH§,¶; VanVeldhuisen, Paul C. PhD; Blodi, Barbara A. MD

doi: 10.1097/IAE.0b013e318263d106
Original Study

Purpose: To investigate the prevalence of venous collaterals after branch and central retinal vein occlusion, assess the association of venous collaterals with other clinical features (including visual acuity), and determine if treatment with intravitreal corticosteroids influences the development of new venous collaterals.

Methods: Review of data from two multicenter randomized clinical trials in the Standard of Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study.

Results: Statistically significant associations of venous collaterals and visual acuity at baseline or at follow-up were not found. Treatment with intravitreal triamcinolone acetonide did not appear to influence the development of venous collaterals.

Conclusion: In contrast to some previous reports, development of venous collaterals did not demonstrate an independent association with visual acuity in eyes with branch retinal vein occlusion or central retinal vein occlusion in the SCORE Study. Intravitreal steroid effects do not appear to influence the development of venous collaterals.

In a review of data from two multicenter clinical trials, presence or development of venous collateral channels was not associated with baseline or change in visual acuity in eyes with branch or central retinal vein occlusion. Intravitreal corticosteroid injection did not influence the development of new venous collaterals.

*Medical College of Wisconsin, Milwaukee, Wisconsin

The EMMES Corporation, Rockville, Maryland

University of Wisconsin, Madison, Wisconsin; and

Departments of§Ophthalmology

Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.

Reprint requests: Paul C. VanVeldhuisen, PhD, The EMMES Corporation, 401 North Washington Street, Suite 700, Rockville, MD 20850; e-mail: score@emmes.com

Supported by the National Eye Institute (National Institutes of Health, Department of Health and Human Services) grants 5U10EY014351, 5U10EY014352, and 5U10EY014404. Support also provided in part by Allergan, Inc, through donation of investigational drug and partial funding of site monitoring visits and secondary data analyses. Supported in part by an unrestricted grant to the Medical College of Wisconsin from Research to Prevent Blindness, Inc, New York, NY.

The authors have no conflicts of interest to disclose.

© The Ophthalmic Communications Society, Inc.